WIN 54954
Based on 1 Customer Validation
WIN 54954 is an orally active and broad-spectrum antipicornavirus agent. WIN 54954 is effectiveness against human rhinovirus, echovirus 9 and enterovirus infections.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.14%
- CAS No.: 107355-45-3
- Formule: C18H20Cl2N2O3
- Masse moléculaire:383.27
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-13784
PirodavirPicornavirus Inhibitor -
HY-19952
PleconarilCapsid Inhibitor -
HY-106254
VapendavirEnteroviral Capsid Binder -
HY-106161
RupintrivirHRV 3C Protease Inhibitor -
HY-104074
PocapavirCapsid Inhibitor -
HY-106296R
WIN 54954 (Standard)Antipicornavirus Agent -
HY-N2562
NorwogoninEnterovirus 71 Inhibitor -
HY-128382
Brilliant Black BNAntiviral Agent -
HY-19952R
Pleconaril (Standard)Capsid Inhibitor -
HY-N0306
Hederasaponin BAntiviral Agent -
HY-16561A
cis-ResveratrolEnteroviruses Inhibitor -
HY-N2036
MosloflavoneEV71 Inhibitor
Activité biologique
Description
In Vitro
WIN 54954 reduces plaque formation of 50 of 52 rhinovirus serotypes (MICs ranges from 0.007 to 2.2 μg/mL)[1]. WIN 54954 inhibits 15 commonly isolated enteroviruses, with an EC80 of 0.06 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 107355-45-3
-
Appearance Solid
-
Masse moléculaire 383.27
-
Formule C18H20Cl2N2O3
-
Color White to off-white
-
SMILES
ClC1=C(OCCCCCC2=CC(C)=NO2)C(Cl)=CC(C3=NCCO3)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (260.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Woods MG, et, al. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74. [Content Brief]
[2]. Fechner H, et, al. Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. Molecules. 2011 Oct 11;16(10):8475-503. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6091 mL | 13.0456 mL | 26.0913 mL | 65.2282 mL |
| 5 mM | 0.5218 mL | 2.6091 mL | 5.2183 mL | 13.0456 mL | |
| 10 mM | 0.2609 mL | 1.3046 mL | 2.6091 mL | 6.5228 mL | |
| 15 mM | 0.1739 mL | 0.8697 mL | 1.7394 mL | 4.3485 mL | |
| 20 mM | 0.1305 mL | 0.6523 mL | 1.3046 mL | 3.2614 mL | |
| 25 mM | 0.1044 mL | 0.5218 mL | 1.0437 mL | 2.6091 mL | |
| 30 mM | 0.0870 mL | 0.4349 mL | 0.8697 mL | 2.1743 mL | |
| 40 mM | 0.0652 mL | 0.3261 mL | 0.6523 mL | 1.6307 mL | |
| 50 mM | 0.0522 mL | 0.2609 mL | 0.5218 mL | 1.3046 mL | |
| 60 mM | 0.0435 mL | 0.2174 mL | 0.4349 mL | 1.0871 mL | |
| 80 mM | 0.0326 mL | 0.1631 mL | 0.3261 mL | 0.8154 mL | |
| 100 mM | 0.0261 mL | 0.1305 mL | 0.2609 mL | 0.6523 mL |
WIN 54954 Related Classifications
HY-106296 Related Classifications
Powered by Bioz